Sichuan Biokin Pharmaceutical Co.,Ltd. (SHA:688506)

SHA:688506 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3,150	3,220	403.96	1,005	154.22	47.2
Short-Term Investments	2,359	2,533	-	-	-	-
Trading Asset Securities	-	-	-	-	-	197.54
Cash & Short-Term Investments	5,509	5,753	403.96	1,005	154.22	244.74
Cash Growth	-6.64%	1324.16%	-59.79%	551.49%	-36.99%	-0.83%
Accounts Receivable	87.96	138.71	137.85	267.92	134.95	226.49
Other Receivables	31.92	34.33	3.9	5.14	2.95	0.64
Receivables	119.87	173.05	141.75	273.06	137.9	227.13
Inventory	184.38	162.19	140.91	101.33	82.33	65.77
Other Current Assets	459.48	218.87	89.2	47.22	49.36	33.21
Total Current Assets	6,272	6,307	775.82	1,426	423.81	570.85
Property, Plant & Equipment	655.61	573.09	534.79	420.26	404.98	380.91
Other Intangible Assets	29.39	26.68	28	29.53	31.16	32.88
Long-Term Deferred Tax Assets	187.28	179.2	76.18	83.23	65.8	48.2
Long-Term Deferred Charges	22.2	18.4	1.82	1.79	1.16	0.67
Other Long-Term Assets	18.07	32.79	8.5	30.28	24.54	8.47
Total Assets	7,185	7,137	1,425	1,991	951.46	1,042
Accounts Payable	176.01	219.25	160.17	128.85	45.96	67.96
Accrued Expenses	576.82	437.25	257.88	244.81	139.81	204.43
Short-Term Debt	250.18	595.5	275.12	155.13	161.23	150.21
Current Portion of Long-Term Debt	234.23	235.28	174.37	30.47	0.02	-
Current Portion of Leases	15.13	20.19	46.13	68.82	24.23	-
Current Income Taxes Payable	0.29	14.13	0.01	4.96	1.54	10.31
Current Unearned Revenue	356.82	356.13	8.67	17.42	10.78	18.1
Other Current Liabilities	102.78	102.21	131.48	86.74	87.75	81.44
Total Current Liabilities	1,712	1,980	1,054	737.2	471.32	532.45
Long-Term Debt	2,572	1,189	183.92	239.96	50	-
Long-Term Leases	45.19	28.13	8.65	52.95	51.42	-
Long-Term Unearned Revenue	45.18	42.27	15.63	13.29	31.04	37.24
Long-Term Deferred Tax Liabilities	2.67	1.94	-	0.08	-	0.08
Other Long-Term Liabilities	8.61	9.73	11.19	14.05	15.81	20.14
Total Liabilities	4,386	3,251	1,273	1,058	619.61	589.91
Common Stock	401	401	401	401	360.9	360.9
Additional Paid-In Capital	916.14	885.84	858.69	858.55	14.17	14.07
Retained Earnings	1,481	2,599	-1,109	-328.45	-45.98	74.01
Comprehensive Income & Other	1.14	0.53	1.13	2.79	2.76	3.1
Total Common Equity	2,799	3,886	151.87	933.89	331.85	452.08
Shareholders' Equity	2,799	3,886	151.87	933.89	331.85	452.08
Total Liabilities & Equity	7,185	7,137	1,425	1,991	951.46	1,042
Total Debt	3,117	2,069	688.19	547.33	286.91	150.21
Net Cash (Debt)	2,392	3,685	-284.23	457.41	-132.69	94.53
Net Cash Growth	-49.53%	-	-	-	-	82.72%
Net Cash Per Share	5.97	9.19	-0.71	1.26	-0.37	0.27
Filing Date Shares Outstanding	401	401	401	401	360.9	344.56
Total Common Shares Outstanding	401	401	401	401	360.9	344.56
Working Capital	4,560	4,327	-278.01	689.14	-47.51	38.4
Book Value Per Share	6.98	9.69	0.38	2.33	0.92	1.31
Tangible Book Value	2,769	3,859	123.88	904.36	300.69	419.2
Tangible Book Value Per Share	6.91	9.62	0.31	2.26	0.83	1.22
Buildings	325.58	325.3	304.56	302.23	300.82	252.7
Machinery	668.63	640.12	554.25	439.83	419.75	363.73
Construction In Progress	92.08	35.51	81.37	67.21	18.18	76.71

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.